Analyst firms · Credit Suisse · ESPR

Credit Suisse ESPR price target and rating history

Esperion Therapeutics Inc. (ESPR) · Health Care

Credit Suisse rates Esperion Therapeutics Inc. (ESPR) Neutral with a $7 price target, as of its latest action on Mar 7, 2023. It has published 5 rating actions on ESPR since October 2021, including 1 upgrade and 2 downgrades.

Current rating
Neutral
Price target
$7
Median target, all firms
Too few
Actions on ESPR
5

Credit Suisse price target on ESPR

$11$8.50$620222023202420252026
Credit Suisse price target on ESPR, each point a stated target, October 2021 to March 2023.

Every Credit Suisse rating on ESPR

How other firms rate ESPR

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightNeutralMay 1, 2026
Piper SandlerOverweight$9Nov 25, 2025

Questions about Credit Suisse and ESPR

What is Credit Suisse's price target for ESPR?
Credit Suisse's latest stated price target for Esperion Therapeutics Inc. (ESPR) is $7, from its action on Mar 7, 2023.
What is Credit Suisse's rating on ESPR?
Credit Suisse rates ESPR Neutral, a neutral rating, as of Mar 7, 2023.
When did Credit Suisse last change its view on ESPR?
On Mar 7, 2023, Credit Suisse upgrades to Neutral from Underperform, price target $6.50 to $7.

More ESPR rating histories

All Credit Suisse ratingsESPR news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.